An elderly person is vaccinated with the Pfizer BioNTech Covid-19 vaccine at a nursing home in Norway. Photo: EPA-EFE An elderly person is vaccinated with the Pfizer BioNTech Covid-19 vaccine at a nursing home in Norway. Photo: EPA-EFE
An elderly person is vaccinated with the Pfizer BioNTech Covid-19 vaccine at a nursing home in Norway. Photo: EPA-EFE
Nathan Bartlett
Opinion

Opinion

Nathan Bartlett

Pfizer coronavirus vaccine and frail people: too early to make firm conclusions

  • Reports of about 30 deaths among elderly people who took the Pfizer-BioNTech Covid-19 vaccine in Norway have raised safety concerns
  • But while it may not be the best choice for frail people, the vaccine should ideally be considered on a case-by-case basis

An elderly person is vaccinated with the Pfizer BioNTech Covid-19 vaccine at a nursing home in Norway. Photo: EPA-EFE An elderly person is vaccinated with the Pfizer BioNTech Covid-19 vaccine at a nursing home in Norway. Photo: EPA-EFE
An elderly person is vaccinated with the Pfizer BioNTech Covid-19 vaccine at a nursing home in Norway. Photo: EPA-EFE
READ FULL ARTICLE
Nathan Bartlett

Nathan Bartlett

Nathan Bartlett is Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle in Australia, and head of the Viral Immunology and Respiratory Disease group. He is based at the Hunter Medical Research Institute. He also retains an honorary academic appointment at Imperial College London, UK to continue collaborative research.